Table 4.

Therapeutic regimens used to treat patients with PIK3CA mutations

RegimenMechanism of actionPatients (case no.a)%Reference
TemsirolimusmTORC1 inhibitor5 (4, 10, 11, 15, 17)29NCT00877773
Temsirolimus, bevacizumabmTORC1 inhibitor, anti-VEGF monoclonal antibody2 (8, 13)12NCT00610493
Temsirolimus, liposomal doxorubicin, bevacizumabmTORC1 inhibitor, anti-VEGF monoclonal antibody, topo II alpha inhibitor8 (1, 3, 5, 12, 16, 18, 20, 21)47NCT00761644
Temsirolimus, topotecan, bortezomibmTORC1 inhibitor, topoisomerase I inhibitor, proteasome inhibitor1 (25)6NCT00770731
XL147, carboplatin, paclitaxelPI3K inhibtor, alkylating agent, microtubule stabilizing agent1 (6)6Wheler and colleagues (11)

NOTE: NCT, clinicaltrials.gov identifier.